Introduction
Mammalian brain function can only be sustained if neuronal demands of glucose and oxygen supply are sufficiently and promptly fulfilled. Therefore, functional hyperemia, the brain's capability to dynamically adjust microvascular blood flow in response to the metabolic demands of active neurons by means of neurovascular coupling, is crucial. Consequently, alterations and dysfunctions in neurovascular coupling and cerebrovascular regulation have been proposed to play a key role in the process of ageing (D'Esposito et al. 2003) as well as for stroke, hypertension, diabetes, and hyperlipidemia (Claus et al. 1998 ). These diseases also represent severe risk factors for vascular pathologies (Shantaram 1999) . Furthermore, neurovascular coupling has been shown to play a decisive role in pathologies such as Alzheimer's disease (Iadecola 2004) and ischemic stroke (Vavilala et al. 2002) . Investigating mechanisms regulating cerebral blood flow (CBF) might thus shed light on severe, complex, and in part heritable pathologies such as Alzheimer's disease. Additionally, detecting genetic determinants of neurovascular coupling is important for functional imaging techniques that indirectly investigate brain activity by modeling hemodynamic responses (HRs). Functional magnetic resonance imaging (fMRI) and other related techniques rely on measuring the HR as a surrogate of neural activity and critically depend on comparable processes and effectiveness of neurovascular coupling in all subjects.
In the local control of blood microcirculation underlying neurovascular coupling, a central role of glutamatergic neuronto-astrocyte signaling has been shown in rodents (Zonta, Angulo, et al. 2003; Haydon and Carmignoto 2006; Rossi 2006; Takano et al. 2006; Gordon et al. 2007; Petzold et al. 2008) . Glutamate diffusing from interneuronal synapses activates astrocytic metabotropic glutamate receptors that trigger a Ca ++ wave reaching astrocytic endfeet (Nimmerjahn 2009 ). Furthermore, purinergic receptors and gap junctions have been shown to be involved in the regulation of astrocytic Ca ++ (Simard et al. 2003 ).
The triggered increase in Ca ++ levels induces secretion of vasoactive molecules from astrocytic endfeet onto vascular smooth muscle cells (VSMCs) surrounding arterioles causing vasodilation (Simard et al. 2003; Zonta, Angulo, et al. 2003) and vasoconstriction (Haydon and Carmignoto 2006; Gordon et al. 2007; Nimmerjahn 2009 ), respectively. Specifically, the Ca ++ increase leads to production of arachidonic acid (AA) from which a multitude of vasoactive molecules are derived. Here, main enzymes involved in these AA cascades are cyclooxygenase (COX) (COX-1 and COX-2), cytochrome P450 epoxygenase, and smooth muscle cytochrome P450 omega-hydroxylase (Haydon and Carmignoto 2006; Koehler et al. 2009 ).
Beside the vasoactive products of AA pathways, K + channels at astrocytes as well as at VSMC have been shown to play a role in arteriolar dilation and constriction following astrocytic Ca ++ increase (Filosa et al. 2006; Girouard et al. 2010) . Furthermore, while glutamate appears to play a major role for triggering astrocytic pathways of neurovascular coupling, other neurotransmitters have been shown to also modulate neurovascular signaling. For instance, neuronal release of nitric oxide (NO), COX-2 metabolites, or vasoactive intestinal peptide has been shown to influence neurovascular coupling in astrocytes and VSMC (Koehler et al. 2009 ). Some of these different pathways and factors putatively involved in neurovascular coupling have been suggested to act, at least partly, in parallel (Leithner et al. 2009 ). Current models of neurovascular coupling linking neuronal activity to CBF are complex and multifactorial. Moreover, whether genetic variation of key molecules involved in neurovascular coupling modulates its effectiveness-and thereby the hemodynamic phenotype-has not been investigated yet. As a promising starting point to investigate this issue, the impact of genotypes that decrease metabolic rates of key enzymes involved in neurovascular coupling could be studied: COXs are the ratelimiting enzymes converting AA to prostaglandin-H 2 , the precursor for several vasoactive prostanoids and may therefore be crucial for the translation of neural activity and astrocytic Ca ++ signaling, respectively, into vasomotor responses underling functional hemodynamics. By combining selective pharmacological inhibition with local perfusion measurements, it has been shown in vivo that astrocyte-mediated vasodilation depends on the isoform COX-1 in mice (Rossi 2006; Takano et al. 2006; Petzold et al. 2008) . However, studies with transgenic (knockout) mice suggest that the isoform, COX-2, is predominantly involved in neurovascular coupling. This obviously hampers a straightforward interpretation of the role of each COX isoform (Niwa et al. 2000 (Niwa et al. , 2001 Stefanovic et al. 2006) . Based on previous findings emphasizing the role of COX-1 for neurovascular coupling (Rossi 2006; Takano et al. 2006; Petzold et al. 2008) , we used an ''Imaging Genetics'' approach to investigate the impact of a genetic variation of the COX-1 gene on functional HRs following visual checkerboard stimulation in humans.
Generally, the enzymatic efficiency of COX-1 is determined on the genetic level (Lee et al. 2007 ). The human COX-1 gene contains 5 functional nonsynonymous single-nucleotide polymorphisms (SNPs) reducing COX-1 enzymatic function by 30--65% (R53H, R78W, K185T, G230S, L237M) in vitro. Although in vivo or ex vivo evidence of changes in AA metabolism due to these COX-1 genotypes are still missing, these nonsynonymous SNPs in COX-1 may represent promising candidates for investigating genetic associations with vascular diseases and neurovascular coupling. We chose to genotype for L287M in the COX1 gene due to its profound impact (methionine alleles reduce COX-1 function by 51 ± 3%) shown in vitro (Lee et al. 2007) . Consistent with pharmacological studies, we hypothesized COX1 genotype-dependent decrease in COX-1 function to be associated with altered functional HR, specifically, decreased HR amplitude and increased HR latency following visual stimulation in humans. Following this approach, we aimed to indirectly infer an impact of COX1 genotype on neurovascular coupling efficiency linking neuronal activation to functional HR following visual stimulation.
Participants and Methods

Genotyping
Genomic DNA was extracted from whole-blood samples (Miller et al. 1999 ) of 306 healthy adult Caucasian subjects. We genotyped the DNA samples for a SNP (rs5789; L237M) in exon 7 of the COX-1 gene (also prostaglandin-endoperoxide synthase-1 [PTGS-1]). The genotyping procedure involved polymerase chain reaction (PCR), enzymatic digestion, and gel electrophoresis described below. All genotypes were scored by 2 independent readers by comparison to sequence-verified standards. Participants were classified by the allelic variant of decreased COX-1 function (237M). Of all 306 DNA samples, 20 were found to be heterozygous for the allelic variant of interest (237M: minor allele frequency [MAF] = 3.3%).
PCR was performed on a TGradient Thermocycler (Biometra GmbH) with 35 cycles at 95°C (45 s), 64.5°C (45 s), and 72°C (45 s), with a 3-min final extension at 72°C. A 270-bp segment within exon 7 of COX-1 was amplified using the following primers: forward: 5#-AGATGGGTCCTGGCTTAC-3#; reverse: 5#-ACCCCTCCCTCTGCCCTAC-3#. The 25-ll reaction Eppendorf cups contained 50 ng DNA, 250 lM deoxyribonucleoside triphosphates (dNTPs) (Promega), 1.5 mM MgCl 2 buffer (Biorad), 8 pmol per primer (Metabion International), and 0.4 U Taq DNA polymerase (Biorad); 4 lL of each PCR product was validated on a 1.5% agarose gel (Biozym Scientific GmbH) before digestion; 10 lL PCR product, 1 lL Hpy188III restriction enzyme, 2 lL bovine serum albumin (1:10), 2 lL NEB4 buffer (103) (digestion enzyme/buffer: New England Biolabs), and 5 lL ddH 2 O were incubated for 3 h at 37°C. Digestion of the 270-bp PCR product resulted in 200 bp + 60 bp + 10 bp fragments when adenine (A; corresponding to the 237M allele) and in 110 bp + 90 bp + 60 bp + 10 bp fragments when cytosine (C; corresponding to the 237L allele) was present at nucleotide position 10476 relative to the transcriptional start site.
Sequencing
Prior to DNA sequencing of subjects enrolled/participating in the functional near-infrared spectroscopy (fNIRS) measurement (n = 18), the genomic regions containing the SNPs of interest (Lee et al. 2007) were amplified using PCR. The 25-lL PCR assays included: 200 lM dNTPs, 3 lL DNA, and 1 pair of forward and reverse primers (each primer 5 pmol per assay):
Cycling conditions were 96°C (120 s) followed by 30 cycles at 96°C (20 s), 58°C (20 s), and 72°C (20 s), final extension at 4°C.
The PCR product was validated on a 1% agarose gel before digestion; 4 lL PCR product and 0.5 lL EXO/SAP (Amersham Biosciences Europe GmbH) were incubated at 37°C for 15 min. Enzymes were inactivated at 96°C (3 min incubation); 2 lL of the digested PCR product were sequenced using Q-Kit (Qiagen) and 5 pmol of the forward primer. The sequencing products were separated on a CEQ8000 (BeckmanCoulter).
In summary, we genotyped 306 DNA samples of healthy subjects for L237M (rs5789; exon 7) using standard genotyping protocols as it has been shown to have the highest MAF of the functional and nonsynonymous SNPs (about 4%) within the COX-1 gene (Lee et al. 2007 ). Of all 306 DNA samples, 20 were found to be heterozygous for the allelic variant of interest (237M: allele frequency = 3.3%).
Participants
The 20 heterozygous carriers of the 237M allele were contacted and asked to participate in the study. Ten heterozygote carriers agreed to participate. Due to poor quality of the fNIRS data (as rated for each subject on a 10-point scale by 2 blind, independent raters), one of these subjects had to be excluded from further analysis. For the control group, thus, 9 homozygous carriers of COX-1 L237 (L/L) were selected as to match the experimental group in regard to gender (6 females in each group), age (U = 26.50; P = 0.232), and smoking status (1 smoker in each group). Overall, 18 subjects between 18 and 28 years of age (mean: 25 years) participated in the study. Participants were instructed not to drink coffee on the day of the experiment and were currently not taking any medication known to alter cerebral blood flow. Furthermore, all subjects had normal or corrected to normal vision and none reported to have any history of neurological or psychiatric disorders. Participants were informed about the nature of the experiment as well as the operating mode of the NIRS instrument before giving written informed consent. They were briefly instructed to remain relaxed and to avoid any major body movement. The investigation was in accordance with the latest version of the Declaration of Helsinki and was approved by the Ethics Committee of the University of Wuerzburg.
The study was conducted using a double-blind design to ensure that at the time of the experiment, neither the subjects nor the investigator conducting the measurement knew to which genotype group the subject belonged.
Functional Paradigm
We conducted a visual checkerboard stimulation paradigm that has been used previously (Plichta et al. 2007 ). Specifically, participants viewed a series of checkerboards, each for 2 s, reversing in contrast at 8 Hz. This was followed by an interstimulus interval (ISI) during which a uniformly gray colored screen was presented for a variable duration (4--9 s, average: 6.5 s). Michelson contrast ratios of the checkerboards were 97% (high contrast) and 8% (low contrast). The ISI screen was set to 0% contrast. Additionally, the protocol included 50 null events with 0% contrast. As we did not intend to draw conclusions based on any parametric variation of the stimuli, the 40% contrast condition used previously was omitted in this study. Furthermore, the number of trials in each of the remaining conditions was increased from 30 to 50 in comparison to the experiment conducted previously (Plichta et al. 2007 ). Subjects were instructed to focus on a fixation cross in the center of the screen. To prevent decline in attention during the stimulation experiment of 23-min duration, participants were asked to indicate with a button press that contrast level (high or low contrast) they had perceived after each stimulus presentation. Behavioral data of one subject was unavailable due to technical error (see Results for details).
Data Acquisition and Statistical Analysis
During visual stimulation, occipital O 2 Hb concentration was continuously measured using fNIRS. The fundamentals of fNIRS and of the continuous wave system (ETG-4000; Hitachi Medical Co.) used to measure cortical oxyhemoglobin (O 2 Hb) changes are described in detail elsewhere (Hoshi 2003; Obrig and Villringer 2003; Plichta et al. 2006) . We used a 52-channel probe set, an interoptode distance of 30 mm and a sampling rate of 10 Hz. In order to optimize positioning of the fNIRS probe set on each subjects' head, a functional localizer was utilized. This procedure ought to ensure that the visually evoked fNIRS activation pattern is most reliably measured by an array of 8 channels covering the area of the occipital cortex of the left and right hemispheres (Plichta et al. 2007 ) (We tested this assumption and were able to confirm the expected O 2 Hb concentration change in each the 8 specified channels using a one-sample t-test and applying Bonferroni correction for all 52 tests [1 per channel; t 17 > 3.89; P < 0.001], while no channel outside the region of interest reached significance [t 17 < 3.60; P > 0.001].). The mean of these 8 channels covering the primary visual cortex forms the basis for all further analyses. All calculations were done using Matlab 7.0 (Math Works) and Brain Vision Analyzer 1.05 (Brain Products). Prior to the analysis, data were band-pass filtered between 0.02 and 0.7 Hz (Plichta et al. 2006) , segmented (length of segments = 20 s), and averaged according to stimulation condition using baseline correction based on the 2 s prior to stimulus onset. This procedure yielded a mean HR in the time interval following the stimulus onset for each condition and subject.
Based on this data, the O 2 Hb concentration change was defined as the mean amplitude of the HR in an interval from 4 to 10 s after stimulus onset thereby reliably covering the peak of the HR (Fox et al. 1988; Heeger and Ress 2002) . The amplitude of the HR (O 2 Hb amplitude) was determined using the Brain Vision Analyzer automatic peak detection algorithm. The amplitude of the undershoot following the HR was calculated analogously searching for the minimum value following the peak. The latency of the HR was defined as the latency of the peak of the HR following visual stimulation.
Statistical analysis was conducted using Mann--Whitney U tests (yielding the test statistic U) to compare the genotype groups and Wilcoxon signed-ranks tests for one-sample and repeated-measures analysis (yielding the test statistic Z). For each test, the respective test statistic is provided together with the exact P value. As we had directed hypotheses concerning O 2 Hb amplitude in the L/M compared with the L/L group as well as concerning O 2 Hb concentration change, one-tailed P values are given in these cases, while all other P values are two tailed. An a-level of 5% was used in all analysis (respective test statistics are provided in parentheses).
Results
Behavioral Data Subjects correctly identified the contrast level on 99.1% of all trials. No subject made more than 3 mistakes in any of the conditions. Due to technical failure, behavioral responses of one subject were not recorded. Visual inspection of this subject's O 2 Hb concentration change maps showed a reliable activation within the primary visual cortex comparable with that of all other participants in the respective conditions. An interview at the end of the experiment did also not provide any reason to doubt the subject's understanding of the instructions nor ability to distinguish between the contrast levels.
Functional Imaging Data
As expected, visual stimulation induced a hemodynamic increase of O 2 Hb concentration in the subjects' primary visual cortex (Z = 3.46, P < 0.001). Further investigating this effect, a greater increase in O 2 Hb concentration could be found for high than for low-contrast checkerboard stimulation (Z = 3.33, P < 0.001).
In line with our main hypothesis, both the L/M and the L/L group displayed a hemodynamic increase following highcontrast checkerboard stimulation, while the amplitudes of the HR (O 2 Hb amplitude) significantly differed (U = 18.00, P = 0.025) between the groups (Fig. 1) . Descriptively, L/M carriers showed a 42% decrease in O 2 Hb peak amplitude as compared with L/L carriers.
While the rapid and pseudo-randomized presentation of the stimuli ought to avoid large habituation effects, this difference in O 2 Hb amplitude between the L/M and the L/L groups could be due to the L/M group showing a stronger habituation to the stimulation rather than a genuine decrease in O 2 Hb amplitude. In order to exclude this possibility, we compared linear habituation effects in O 2 Hb amplitude between both groups: No difference between the habituation effects of the 2 genotype groups could be found (low contrast: U = 95, P = 0.436; high contrast: U = 88, P = 0.863).
While an HR was also observed for low-contrast checkerboard stimulation, the O 2 Hb amplitude in this condition did not differ between groups (U = 29.50, P = 0.175). Also, the latencies of the HR were not significantly different for high (U = 28.00, P = 0.297) and low-contrast checkerboard stimulation (U = 30.00, P = 0.387).
In order to identify potential confounding effects by the 4 other functional SNPs known to impact COX-1 function, we additionally sequenced the genomic regions containing these SNPs of interest. Additional allelic variants affecting the enzymatic function of COX-1 were not present in the fNIRS sample of 18 subjects (for details, see Supplementary Results online).
Discussion
We were able to reliably elicit an O 2 Hb concentration change in response to visual checkerboard stimulation in the human primary visual cortex. Investigating the impact of the COX-1 genotype on functional hemodynamics, L/M carriers showed a substantial decrease of O 2 Hb amplitude in response to highcontrast visual stimulation compared with L/L. Thus, using an Imaging Genetics approach, we were able to provide evidence toward an impact of COX-1 genotype on hemodynamic phenotype and to indirectly infer that COX1 genotype modulates neurovascular coupling in humans. However, as a multitude of mechanisms and vasoactive factors have been implicated in neurovascular coupling, our finding of a substantial effect of COX1 genotype on HRs in human visual Cerebral Cortex July 2011, V 21 N 7 1661 cortex has to be discussed in the light of other putative regulatory mechanisms and permissive factors:
One main mechanism of neurovascular coupling is thought to involve the spillover of glutamate released from neuronal synapses that was shown to trigger (oscillatory) Ca 2+ waves in perisynaptic astrocytes via metabotropic glutamate receptors (Nakahara et al. 1997; Haydon 2001; Zonta, Angulo, et al. 2003; Zonta, Sebelin, et al. 2003) . The changes in astrocytic Ca 2+ are crucial for regulating synthesis and/or release of AA via Ca 2+ -dependent stimulation of phospholipase A 2 (Seregi et al. 1987) . Importantly, AA serves as a substrate for different metabolic cascades generating vasoactive agents that have been implicated in neurovascular coupling.
COX-1 oxidizes AA to the prostanoid precursor PGH 2 that is subsequently converted by specific prostanoid synthases, for example, within astrocytic endfeet as shown in mice (Smith and Lands 1972; Simmons et al. 2004; Takano et al. 2006) . COX-1 is constitutively expressed in most mammalian cells, for example, in glia cells, neurons and endothelial cells of the brain and in platelet cells, whereas the isoform COX-2 is highly inducible (in response to proinflammatory and mitogenic factors) (Wu 1995; Pardue et al. 2003) . COX-2 has been shown to also be present in a subset of neurons and endothelial cells in mice and to also contribute to neurovascular coupling (Parfenova et al. 1997; Niwa et al. 2000; Wang et al. 2005; Stefanovic et al. 2006) . Another isoform, COX-3, an alternative splice variant of the COX-1 gene, exists in cerebral cortex of humans, but its role for neurovascular coupling remains unclear, further complicating precise definitions of the role of each isoform for neurovascular coupling. All COX isoforms catalyze the conversion of AA to PGH 2 (Chandrasekharan et al. 2002; Garavito and Mulichak 2003) . By specific prostaglandine synthases, the prostanoid precursor PGH 2 can be further converted to 5 major vasoactive products (Fig. 2) : 1) Vasodilatory AA metabolites that dilate VSMC by opening Ca 2+ -sensitive K + -channels (K Ca ) in the VSMC membrane (Gebremedhin et al. 1992; Tanioka et al. 2000; Li et al. 2002) .
Indicating an important role of PGE 2 astrocytes has been shown to release PGE 2 in response to glutamate triggering vasodilation unless COX is inhibited using irreversible nonselective (aspirin, indomethacin) or selective (sc-560) inhibitors of COX-1 (Zonta, Sebelin, et al. 2003; Blanco et al. 2008) . PGE 2 might furthermore mediate vasodilation following the switch from oxidative to glycolysis metabolism, which has been proposed to underlie neurovascular coupling, because lactate produced by glycolysis inhibits reuptake of PGE 2 from extracellular medium into astrocytes (Gordon et al. 2008) . 2) Vasodilatory prostacyclin (also prostaglandin I) was shown to cause relaxation of cerebral arteriols by mechanisms involving cyclic Adenosine Monophosphate formation and NO and K + regulation (Faraci and Heistad 1998) . Furthermore, the vasoconstrictive factors 3) thromboxane A 2 (TXA 2 ) (Pearce et al. 1989; Ishimoto et al. 1996) and 4) prostaglandin F 2a (PGF 2a ) (Bezzi et al. 1998; Basu 2007; Blanco et al. 2008 ) have been shown to be produced by astrocytes and endothelial cells. Alternative to COX-dependent pathways, AA can be also be converted to 5) vasodilatory epoxyeicosatrienoic acids (EETs) by cytochrome P450 2C11 (CYP 2C11; epoxygenase). EETs like PGE 2 were shown to dilate VSMC by opening K Ca (Gebremedhin et al. 1992; Li et al. 2002; Blanco et al. 2008) . 6) Also, AA can diffuse from astrocytic endfeet to VSMC where cytochrome P450 4A (CYP 4A; x-hydroxylase) generates 20-hydroxyeicosatetraenoic acid (20-HETE) that acts vasoconstrictive by closing K Ca at VSMC (Mulligan and MacVicar 2004; Metea and Newman 2006) .
Beside AA-derived products, several other factors have been shown to play a role for neurovascular coupling. 7) Vasoconstrictive endothelin-1 (ET-1) has been shown to be produced by astrocytes and endothelial cells and to induce AA release (MacCumber et al. 1990; Yoshimoto et al. 1991; DurieuTrautmann et al. 1993; Trevisi et al. 2002) . 8) NO produced by neuronal or endothelial nitric oxide synthase (NOS) has been shown to play a modulator role as it inhibits the synthesis of vasoconstrictive 20-HETE (Cholet et al. 1997; Lindauer et al. 1999 ) permitting EET-dependent vasodilation (Liu et al. 2008 ). However, 9) angiotensin II (AngII) has been shown to disrupt the NO-dependent regulation of the cerebral circulation in mice (Girouard et al. 2007 ). As VSMC K + channels were shown to be crucial for vasoresponses, 10) regulation of local extracellular K + concentrations also plays a role for neurovascular coupling (Filosa and Blanco 2007; Girouard et al. 2010) . 11) Furthermore, several neuropeptides have also been shown to exert vasoactive effects, for example, neuropeptide Y, somatostatin (both vasoconstrictive), and vasoactive intestine peptide (vasodilatory) (Cauli et al. 2004) . VSMC as well as astrocytes have been shown to express various receptors for these neuropeptides released from GABAergic interneurons (Cauli et al. 2004) . While astrocytic endfeet may represent an important stage of neurovascular coupling, neurons, extracellular medium, endothelial cells as well as AA metabolites within the blood have been shown to be involved as well. For instance, enzymes of the AA cascade have also been found in isolated cerebral capillaries. Also, the uptake of AA into brain blood vessels increases in response to muscarinic receptor stimulation (Williams et al. 1998; Vazquez-Tello et al. 2004) . Thus, the effect of COX1 genotype on functional HRs might, in part, also emerge from the level of blood and blood vessels.
Although vasoactive factors and mechanisms of neurovascular coupling are numerous as well as speculative in their interaction, evidence of an important role of COX has been gained from in vivo studies in mice (Simard et al. 2003; Zonta, Angulo, et al. 2003; Haydon and Carmignoto 2006; Rossi 2006; Takano et al. 2006; Gordon et al. 2007 Gordon et al. , 2008 Petzold et al. 2008) . Selective pharmacological inhibition of COX-1 was shown to disrupt dilatory responses of arteries after inducing increased Ca ++ levels in astrocytes of cortical tissue and olfactory glomeruli in mice in vivo (Takano et al. 2006; Petzold et al. 2008) . However, to what extent pharmacological inhibition affected the concentrations of vasoactive COX-1 products derived from AA affecting vasoresponses remained unclear. Combined pharmacological inhibition of COX, NOS, adenosine receptors, CYP450 epoxygenase, and inward rectifier potassium (Kir) channels in rats did only reduce HRs (by two-thirds) while somatosensory evoked potentials and increases in oxygen consumption remain unaffected (Leithner et al. 2009 ). Similarly, COX and NOS inhibition attenuated glutamate-dependent HRs in sensory cortex by about 50% after direct stimulation of transcallosal pathways in rats, without affecting local field potential amplitudes (Hoffmeyer et al. 2007) . In humans, inhibition of COX by indomethacin has been shown to reduce the blood oxygen level--dependent (BOLD) contrast by 34% measured with fMRI during repeated visual checkerboard stimulation (Bruhn et al. 2001) .
Since the present ''Imaging Genetics'' study did not quantify COX products derived from AA or other vasoactive factors, nor directly investigated neurovascular coupling, we can only speculate about mechanisms underlying the differences in HR amplitude between COX-1 genotype groups. Moreover, in vivo evidence of an impact of COX-1 L237M (rs5789) on AA metabolism in astrocytic endfeet and/or endothelial cells is still missing, calling for a cautious interpretation of our findings. To speculate, depending on COX-1 enzymatic efficiency, the metabolic AA cascades (Fig. 2 ) may be differentially involved after an increase in astrocytic Ca ++ subsequent to (glutamatergic) neuronal activity. While the production of, for example, vasodilatory PGE 2 via COX-1 may be reduced, vasoconstrictive products may be increasingly derived from AA. For instance, the diffusion of AA to VSMC may increase where AA is converted to vasoconstricte 20-HETE (Haydon and Carmignoto 2006; Gordon et al. 2007; Koehler et al. 2009 ). Such transient imbalance between opposing vasodilatory and vasoconstrictive factors following AA mobilization in astrocytic endfeet due to COX1 genotype could be one explanation for the present results as well as for the substantially reduced functional HRs in mice and humans after pharmacological inhibition of COX (Bruhn et al. 2001; Takano et al. 2006; Petzold et al. 2008) . For low-contrast visual stimulation that has been shown to elicit relatively decreased activity of the primary visual cortex (Tootell et al. 1998) , no impact of COX-1 genotype was found. Possibly, residual COX-1 function in the L/M heterozygotes, other compensatory mechanisms of neurovascular coupling or COX1 gene expression, may contribute to HRs elicited by relatively lower neural activity Ishikawa et al. 2009 ).
Investigation of genetic variation of COX1 affecting AA metabolism or other vasoactive molecules/mediators involved in neurovascular coupling at different stages, that is, in astrocytes, neurons, VSMC, and blood in humans are sparse or missing. A haplotype of 2 SNPs within the human COX-1 gene (P17L substitution (C50T) and A-842G in the promotor region) was shown to have no significant effect (P = 0.09) on COX-1--dependent PGF 2a formation in platelets but to significantly increase the inhibitory effect of aspirin on PGF 2a formation (P = 0.01) (Halushka et al. 2003) . Carriers of this haplotype were shown to have a lower, but nonsignificant risk for peptic ulcer hemorrhage as well as a lower, but nonsignificant risk for premature myocardial infarction compared with wild type (van Oijen et al. 2006; Motovska et al. 2010) . Similarly, 2 intronic SNPs (rs10306135; rs883484; a-level = 0.0059) of the COX1 gene (L237M not investigated) were found to be associated with proinflammatory PGF 2a formation in a large sample (n = 809) of men. Rs10306135 was furthermore, significantly, associated with a lower prevalence of developing cardiovascular disease (Helmersson et al. 2009 ). Furthermore, the impact of 5 COX-1 SNPs (A-842G, C22T (R8W), G128A (Q41Q), C644A (G213G) and C714A (L237M)) in patients with cardiovascular disease who were taking aspirin was investigated. Here, a haplotype of 4 SNPs (not including L237M due to its low MAF of 3--4%) modulated AA-induced platelet aggregation and thromboxane generation in response to aspirin (Maree et al. 2005) . However, although functionally characterized in vitro investigation of functionality of COX-1 L258M in vivo and its impact at critical stages of neurovascular coupling (for instance on astrocytic endfeet and VSMC) are currently missing. As outlined above, mechanisms and factors putatively involved in neurovascular coupling are numerous. Genetic variations (e.g., SNPs) of each of these factors largely outnumber the mechanisms and factors involved in neurovascular coupling. Therefore, an Imaging Genetics approach as utilized in this study may represent a possibility to explore, select, and evaluate gene variants of interest that modulate neurovascular coupling and, thus, the functional hemodynamic phenotype. Similarly, Imaging Genetics has been proposed as a tool to identify genetic factors (of currently unknown in vivo function) impacting cognitive processing in psychiatric Cerebral Cortex July 2011, V 21 N 7 1663 diseases as measured using methods of neuroimaging (Potkin et al. 2009 ). Based on such identifications precise in vivo and in vitro mechanisms of the genetic variants as well as clinical associations (which typically require large sample sizes) could be subsequently investigated (Bigos and Weinberger 2010) . For instance, ageing (D'Esposito et al. 2003) as well as hypertension, diabetes, and hyperlipidemia (Claus et al. 1998 ) affect the BOLD signal by altering CBF and neurovascular coupling and, thus, are risk factors for vascular pathology (Shantaram 1999) . Furthermore, neurovascular coupling has been shown to play a decisive role in pathologies such as Alzheimer's disease (Iadecola 2004) and ischemic stroke (Vavilala et al. 2002) . Therefore, the investigation of genetic variants affecting neurovascular coupling might help to identify (genetic) risk factors not only for vascular pathologies alone but also for neurodegenerative and psychiatric disorders. Here, by altering the interplay between vasoactive AA pathways, decreased COX-1 function may impact the biological variability of the neurovascular system (Maxim et al. 2005) controlling functional hemodynamics and cerebral circulation implicated in afore mentioned severe pathologies.
Furthermore, pharmacological influences on neurovascular coupling as nonsteroid anti-inflammatory drugs (e.g., aspirin, which irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2) (Chandrasekharan and Simmons 2004) , nicotine or psychopharmacological medication (e.g., antidepressants), pose challenges to the domain of functional neuroimaging (D'Esposito et al. 2003) . Here, 2 important techniques (fMRI and fNIRS) rely on measuring the HR as a surrogate of neural activity and therefore critically depend on neurovascular coupling translating neuronal activity into vasodilation-induced changes of blood oxygen levels. For example, caffeine, even in small doses has been shown to decrease the resting CBF by 20--30% and the BOLD baseline signal by 4.4% (Cameron et al. 1990 ). On the contrary, caffeine can also exaggerate task-induced BOLD response in a nonlinear fashion (Laurienti et al. 2002) due to larger differences between states of resting and activity (Mulderink et al. 2002) . If not excluded from studies using functional neuroimaging, these pharmacological effects on neurovascular coupling extremely complicate the interpretation of functional HRs and deducing information about neuronal activity might no longer be possible. Consequently, genetic variants, which, for example, decrease efficiency of neurovascular coupling similar to pharmacological influences, also reduce interpretability of neuroimaging results. Identification of such genetic variants could therefore improve explaining error variance of fMRI and fNIRS data. In this context, our results underline the importance of choosing HR models flexible enough to accommodate interindividual differences in neurovascular coupling and to carefully consider other (i.e., not task related) sources of between-group differences especially when inferences are based on small sample sizes as is common in cognitive neuroimaging studies using fMRI or fNIRS.
Generally, the Imaging Genetics approach utilized here provides a means to indirectly study the mechanisms of neurovascular coupling in humans. Specifically, we were able to provide evidence toward an impact of COX-1 genotype on the functional hemodynamic phenotype in humans. Building on this, further studies might yield a more complete picture of the specific processes essential for neurovascular coupling in humans.
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